Allogeneic leukemia cells

Allogeneic leukemia cells are leukemic blasts harvested from a donor and used as a therapeutic agent, most commonly in the form of irradiated whole-cell vaccines for treating hematologic malignancies (NCI Dictionary of Cancer Terms). These cells serve as a comprehensive source of leukemia-associated antigens (LAAs) and minor histocompatibility antigens, which are presented to the recipient's immune system to trigger a polyclonal anti-tumor response (Lichtenegger et al., 2017). Often, these cells are genetically modified to secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) or are administered alongside adjuvants to enhance the recruitment and activation of dendritic cells (Ho et al., 2009). This therapeutic strategy is designed to elicit a graft-versus-leukemia (GvL) effect, targeting minimal residual disease that may persist after standard chemotherapy or hematopoietic stem cell transplantation (PubMed). The use of allogeneic cells rather than autologous cells allows for the inclusion of minor histocompatibility antigens, which can provide a more potent immune stimulus (StatPearls). While clinically significant, allogeneic leukemia cells are considered a complex biological product or a therapeutic modality rather than a specific molecular target like a receptor or enzyme (UniProt).

Other names

Allogeneic leukemic blastsAllogeneic myeloblastsDonor-derived leukemia cellsAllogeneic whole-cell leukemia vaccine

Induction of a polyclonal host immune response against donor-derived leukemia-associated antigens and minor histocompatibility antigens to promote a graft-versus-leukemia effect (Lichtenegger et al., 2017).